BMS-754807
- Generic Name
- BMS-754807
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H24FN9O
- CAS Number
- 1001350-96-4
- Unique Ingredient Identifier
- W9E3353E8J
- Background
BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 77
- Registration Number
- NCT01225172
- Locations
- 🇺🇸
Oncology Care Associates, P.A., Wheaton, Maryland, United States
🇺🇸Presbyterian Hospital Cancer Research, Charlotte, North Carolina, United States
🇺🇸University Of Virginia Health System, Charlottesville, Virginia, United States
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT00908024
- Locations
- 🇺🇸
University Of Wisconsin, Madison, Wisconsin, United States
🇨🇦Local Institution, Toronto, Ontario, Canada
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT00898716
- Locations
- 🇯🇵
Local Institution, Chuo-Ku, Tokyo, Japan
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT00793897
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00788333
- Locations
- 🇬🇧
Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 63
- Registration Number
- NCT00569036
- Locations
- 🇦🇺
Local Institution, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.